Biomica

Biomica ltd, owned by Evogene Ltd is a biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders.In April 2023, Biomica Ltd closed a financing round of $20 million.In December 2022, Biomica Ltd and a subsidiary of Evogene Ltd announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC)